Item 8.01. Other Events.

On January 14, 2021, PDS Biotechnology Corporation (the "Company") issued a press release, a copy of which is filed herewith as Exhibit 99.1 and incorporated herein by reference, announcing the issuance of a white paper regarding the Company's Versamune® platform technology as a cancer immunotherapy. A copy of the white paper is filed herewith as Exhibit 99.2 and incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.





(d) Exhibits.

Exhibit
 Number                 Description

  99.1     Press Release, dated January 14, 2021.
  99.2     White paper, dated January 14, 2021.

--------------------------------------------------------------------------------


                                   Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

PDS BIOTECHNOLOGY CORPORATION

Date: January 14, 2021   By: /s/ Frank Bedu-Addo, Ph.D.
                         Name: Frank Bedu-Addo, Ph.D.
                         Title: President and Chief Executive Officer

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses